Sandoz (SWX:SDZ) Stock May Be 38% Below Fair Value On Biosimilar Growth Plan

Sandoz Group has delivered a 50.1% share price gain over the past year, which naturally puts the spotlight on whether that move is grounded in the cash the business can generate. With the stock now trading around CHF 70.76, the key issue for investors is how that price lines up with an intrinsic value estimate based on its future cash flows.

• The 50.1% one year return means anyone looking at Sandoz Group today is effectively asking whether the recent re rating is fully supported by the cash it can produce over time.
• Management's push to expand the biosimilar portfolio, including new partnerships and a long term plan to grow the range of compounds, can influence assumptions about revenue durability, investment needs and ultimately the cash flow profile behind the stock.
• What if you looked at Sandoz Group through its earnings instead? See why Sandoz Group's 57.9x P/E tells a different valuation story.

The issue now is whether Sandoz Group's current share price is aligned with the intrinsic value suggested by a Discounted Cash Flow (DCF) view of its cash flows.

If you want a wider lens on this kind of cash flow focused story than Sandoz Group alone, compare it with companies in the 170 high quality undervalued stocks

Is Sandoz Group a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model here uses a 2 Stage Free Cash Flow to Equity approach to translate Sandoz Group's projected cash generation into today’s terms. On the cash side, the business is working from last twelve month free cash flow of about US$1.11b and analyst projections that point to higher annual free cash flow by 2030, with growth rates that temper over time in the later years of the forecast.

Those estimates sit alongside the current share price of CHF70.76, and the DCF outcome indicates that the projected cash flows justify a level substantially above where the stock trades today. Because management is pushing hard into a larger biosimilar portfolio and partnerships such as the recent Henlius and mAbxience collaborations, the model is effectively assuming that these pipeline investments convert into durable free cash flow rather than just near term headlines. Find out what Sandoz Group could be worth using our Discounted Cash Flow (DCF) estimate.

The Sandoz Group Narrative: What Would Justify Today's Price?

Narratives for Sandoz Group pick up where the valuation puzzle leaves off and spell out which paths for growth, margins and earnings would justify a price meaningfully higher or lower than today, on Simply Wall St's Community page. Each one frames Sandoz Group's implied fair value as a clear, testable view on how the business might develop over time so you can track whether that story holds up as new information arrives.

Community views on Sandoz Group are split between those who see the pipeline and manufacturing build out as underappreciated and those who focus on pricing, tariffs and legal drag.

Bull case: 6% undervalued

"Regulatory streamlining and investments in advanced in-house manufacturing, notably Slovenia expansion and Just-Evotec acquisition, are expected to lower production costs…"

Discover why this Narrative puts Sandoz Group at 6% undervalued.

Bear case: 28% overvalued

"Ongoing and rising global pressure on drug pricing, compounded by newly confirmed US tariffs on EU generics and biosimilars, is likely to further constrain Sandoz's ability to drive top-line revenue…"

Explore why this Narrative puts Sandoz Group at 28% overvalued.

One more Sandoz Group angle that could change the story

Cash flows and scenarios only go so far if you do not know who is steering Sandoz Group and what targets their pay actually nudges them toward. See who runs Sandoz Group and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com